- Home
- LSPD vs TSHA Comparison
LSPD vs TSHA Comparison
Compare LSPD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSPD
- TSHA
- Stock Information
- Founded
- LSPD 2005
- TSHA 2019
- Country
- LSPD Canada
- TSHA United States
- Employees
- LSPD N/A
- TSHA N/A
- Industry
- LSPD
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- LSPD
- TSHA Health Care
- Exchange
- LSPD Nasdaq
- TSHA Nasdaq
- Market Cap
- LSPD 1.5B
- TSHA 1.4B
- IPO Year
- LSPD 2020
- TSHA 2020
- Fundamental
- Price
- LSPD $11.81
- TSHA $5.00
- Analyst Decision
- LSPD Hold
- TSHA Strong Buy
- Analyst Count
- LSPD 13
- TSHA 9
- Target Price
- LSPD $13.58
- TSHA $10.00
- AVG Volume (30 Days)
- LSPD 547.0K
- TSHA 11.7M
- Earning Date
- LSPD 11-06-2025
- TSHA 11-12-2025
- Dividend Yield
- LSPD N/A
- TSHA N/A
- EPS Growth
- LSPD N/A
- TSHA N/A
- EPS
- LSPD N/A
- TSHA N/A
- Revenue
- LSPD $1,115,677,000.00
- TSHA $8,098,000.00
- Revenue This Year
- LSPD $14.22
- TSHA N/A
- Revenue Next Year
- LSPD $12.03
- TSHA N/A
- P/E Ratio
- LSPD N/A
- TSHA N/A
- Revenue Growth
- LSPD 15.46
- TSHA N/A
- 52 Week Low
- LSPD $7.34
- TSHA $1.05
- 52 Week High
- LSPD $18.96
- TSHA $5.51
- Technical
- Relative Strength Index (RSI)
- LSPD 51.05
- TSHA 61.93
- Support Level
- LSPD $11.01
- TSHA $4.43
- Resistance Level
- LSPD $11.74
- TSHA $5.33
- Average True Range (ATR)
- LSPD 0.40
- TSHA 0.44
- MACD
- LSPD 0.04
- TSHA -0.02
- Stochastic Oscillator
- LSPD 74.32
- TSHA 56.80
About LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.